IACH Focus on Leukemia 2020 | Antibody-based therapy to treat AML: radioimmunoconjugates
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute myeloid leukemia (AML). Antibody therapy has shown to be useful in AML as seen with gemtuzumab ozogamicin that has now been re-approved for adults with newly diagnosed CD33-positive AML and adults and children 2 years and older with relapsed or refractory CD33-positive AML. Other conjugates are in development, such as radioimmunoconjugates. One molecule of particular interest is Iomab-B, monoclonal antibody BC8, targeting CD45 linked to the radioisotope iodine-131. Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Relapsed or Refractory AML) trial (NCT02665065). This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
